| Host: |
Rabbit |
| Applications: |
WB/IHC-P/IF/ICC/ELISA |
| Reactivity: |
Human/Mouse |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Clonality: |
Monoclonal |
| Clone ID: |
S0MR |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.02% Sodium Azide, 0.05% BSA, 50% Glycerol, pH 7.3. |
| Purification: |
Affinity purification |
| Concentration: |
Lot specific |
| Dilution Range: |
WB:1:500-1:1000IHC-P:1:50-1:200IF/ICC:1:50-1:200ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements. |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
EFNA1 |
| Gene ID: |
1942 |
| Uniprot ID: |
EFNA1_HUMAN |
| Immunogen Region: |
1-100 |
| Specificity: |
A synthetic peptide corresponding to a sequence within amino acids 1-100 of human Ephrin A1 (P20827). |
| Immunogen Sequence: |
MEFLWAPLLGLCCSLAAADR HTVFWNSSNPKFRNEDYTIH VQLNDYVDIICPHYEDHSVA DAAMEQYILYLVEHEEYQLC QPQSKDQVRWQCNRPSAKHG |
| Tissue Specificity | Brain. Down-regulated in primary glioma tissues compared to the normal tissues. The soluble monomeric form is expressed in the glioblastoma multiforme (GBM) and breast cancer cells (at protein level). |
| Post Translational Modifications | Undergoes proteolysis by a metalloprotease to give rise to a soluble monomeric form. N-Glycosylation is required for binding to EPHA2 receptor and inducing its internalization. |
| Function | Cell surface GPI-bound ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. Plays an important role in angiogenesis and tumor neovascularization. The recruitment of VAV2, VAV3 and PI3-kinase p85 subunit by phosphorylated EPHA2 is critical for EFNA1-induced RAC1 GTPase activation and vascular endothelial cell migration and assembly. Exerts anti-oncogenic effects in tumor cells through activation and down-regulation of EPHA2. Activates EPHA2 by inducing tyrosine phosphorylation which leads to its internalization and degradation. Acts as a negative regulator in the tumorigenesis of gliomas by down-regulating EPHA2 and FAK. Can evoke collapse of embryonic neuronal growth cone and regulates dendritic spine morphogenesis. |
| Protein Name | Ephrin-A1Eph-Related Receptor Tyrosine Kinase Ligand 1Lerk-1Immediate Early Response Protein B61Tumor Necrosis Factor Alpha-Induced Protein 4Tnf Alpha-Induced Protein 4 Cleaved Into - Ephrin-A1 - Secreted Form |
| Database Links | Reactome: R-HSA-2682334Reactome: R-HSA-3928663Reactome: R-HSA-3928665 |
| Cellular Localisation | Cell MembraneLipid-AnchorGpi-AnchorEphrin-A1Secreted Form: Secreted |
| Alternative Antibody Names | Anti-Ephrin-A1 antibodyAnti-Eph-Related Receptor Tyrosine Kinase Ligand 1 antibodyAnti-Lerk-1 antibodyAnti-Immediate Early Response Protein B61 antibodyAnti-Tumor Necrosis Factor Alpha-Induced Protein 4 antibodyAnti-Tnf Alpha-Induced Protein 4 Cleaved Into - Ephrin-A1 - Secreted Form antibodyAnti-EFNA1 antibodyAnti-EPLG1 antibodyAnti-LERK1 antibodyAnti-TNFAIP4 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
